Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ani Pharmaceuticals (ANIP) Accounts Payables: 2009-2025

Historic Accounts Payables for Ani Pharmaceuticals (ANIP) over the last 17 years, with Sep 2025 value amounting to $69.8 million.

  • Ani Pharmaceuticals' Accounts Payables rose 14.62% to $69.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $69.8 million, marking a year-over-year increase of 14.62%. This contributed to the annual value of $45.7 million for FY2024, which is 24.46% up from last year.
  • Latest data reveals that Ani Pharmaceuticals reported Accounts Payables of $69.8 million as of Q3 2025, which was up 27.90% from $54.6 million recorded in Q2 2025.
  • In the past 5 years, Ani Pharmaceuticals' Accounts Payables ranged from a high of $69.8 million in Q3 2025 and a low of $11.5 million during Q3 2021.
  • In the last 3 years, Ani Pharmaceuticals' Accounts Payables had a median value of $48.7 million in 2024 and averaged $46.7 million.
  • As far as peak fluctuations go, Ani Pharmaceuticals' Accounts Payables fell by 14.47% in 2021, and later spiked by 113.00% in 2022.
  • Over the past 5 years, Ani Pharmaceuticals' Accounts Payables (Quarterly) stood at $23.0 million in 2021, then rose by 27.60% to $29.3 million in 2022, then rose by 25.18% to $36.7 million in 2023, then climbed by 24.46% to $45.7 million in 2024, then increased by 14.62% to $69.8 million in 2025.
  • Its Accounts Payables was $69.8 million in Q3 2025, compared to $54.6 million in Q2 2025 and $53.1 million in Q1 2025.